Press releases
Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS – Overall Survival data lead to partial clinical hold
July 8, 2021
STOCKHOLM — July 8, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announ...
Number of shares and votes in Oncopeptides
June 30, 2021
Stockholm — June 30, 2021 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the company’s...
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
May 26, 2021
Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Wednesday, 26 May 2021. At the Annual General Meeting, the following principal resolutions were passed.
Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021
May 26, 2021
A strong start for PEPAXTO in the US
Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma
May 25, 2021
· According to the Independent Review Committee Assessment, melflufen was non-inferior to pomalidomide on the primary endpoint of Progression Free Survival (PFS) with a Hazard Ratio favoring melflu...
Invitation to presentation of the Q1 2021 results
May 20, 2021
STOCKHOLM — May 20, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish...
Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology
May 19, 2021
STOCKHOLM — May 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announ...
Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting
May 12, 2021
STOCKHOLM — May 12, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announ...
Oncopeptides completes patient enrollment in phase 2 PORT study
May 5, 2021
STOCKHOLM — May 5, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announc...
Number of shares and votes in Oncopeptides
April 30, 2021
Stockholm — April 30, 2021 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the directed issue of 7,000,000 shares, whi...
Oncopeptides publishes the 2020 Annual Report
April 26, 2021
STOCKHOLM — April 26, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today publ...
Annual General Meeting in Oncopeptides AB (publ)
April 26, 2021
The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annua...
Oncopeptides submits application for conditional marketing authorization of melflufen in the EU
April 16, 2021
STOCKHOLM — April 16, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today anno...
Number of shares and votes in Oncopeptides
March 31, 2021
Stockholm — March 31, 2021 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the company’...
Oncopeptides announces that PEPAXTO® is included in new Multiple Myeloma guidelines of National Comprehensive Cancer Network®
March 22, 2021
STOCKHOLM — March 22, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today anno...
Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO®
March 15, 2021
STOCKHOLM — March 15, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today anno...
Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million)
March 10, 2021
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRI...
Oncopeptides intends to carry out a directed share issue
March 9, 2021
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRI...
Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma
March 8, 2021
STOCKHOLM — March 8, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today annou...
FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
February 26, 2021
STOCKHOLM — February 26, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today a...